Search

Your search keyword '"Cecile Rose T. Vibat"' showing total 33 results

Search Constraints

Start Over You searched for: Author "Cecile Rose T. Vibat" Remove constraint Author: "Cecile Rose T. Vibat" Topic oncology Remove constraint Topic: oncology
33 results on '"Cecile Rose T. Vibat"'

Search Results

1. Abstract CT055: PAVO: A phase-II, open label, single arm study of niraparib in patients with locally advanced/metastatic PALB2 mutated tumors

2. Clinical application of a functional 3D ex vivo test to predict therapeutic response in patients with HGG: A progression-free survival analysis

Catalog

Books, media, physical & digital resources

3. Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population

4. INNV-16. CLINICAL APPLICABILITY OF INDIVIDUALIZED DRUG RESPONSE PROFILING UTILIZING EX-VIVO TISSUE-DERIVED 3D CELL CULTURE ASSAYS IN HIGH-GRADE GLIOMA: A SINGLE INSTITUTION CASE SERIES USING 3D-PREDICT RESULTS

5. Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations

6. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

7. Clinical Utility of Target Selector™ ctDNA Testing: Detection of EGFR Mutations via Liquid Biopsy Enabled Targeted Therapy Selection for Patients with Advanced NSCLC

8. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease

9. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

10. Abstract 5597: TargetSelector™ CTC technology demonstrates clinical utility in monitoring treatment response in germ cell tumors (testicular cancer)

11. Performance of Biocept's sample collection for tumor cell analysis

12. Sensitivity of TargetSelector in clinical experience in ctDNA profiling of NSCLC 2000 cases

13. ctDNA detection of EGFR mutations in NSCLC patients using TargetSelector

14. Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders

15. P3.02b-024 Dynamics of EGFR Mutational Load in Urine and Plasma Correlates with Treatment Response in Advanced NSCLC

16. Abstract 3146: Circulating tumor DNA assay performance for detection and monitoring of KRAS mutations in urine from patients with advanced cancers

17. Quantitative urinary KRAS for treatment decisions in patients with metastatic colorectal cancer (mCRC)

18. Abstract 30: Quantitative monitoring of EGFR mutations in urinary circulating tumor DNA enables non-invasive pharmacodynamic assessment of anti-EGFR drug response

19. Abstract B4: Use of urinary circulating tumor DNA (ctDNA) KRAS for monitoring treatment response in patients with metastatic colorectal cancer (mCRC)

20. Abstract 5240: Comparative levels of KRAS mutations circulating tumor DNA for association with overall survival in patients with non-resectable pancreatic cancer

21. Abstract 5238: Methodology for single copy detection and quantitative monitoring of clinically actionable circulating tumor DNA mutations in urine from cancer patients

22. Abstract 5237: Monitoring minimal residual disease by urinary or plasma circulating tumor DNA of KRAS mutation burden in colorectal cancer patients with resectable liver metastases

23. Kinetic monitoring of EGFR T790M in urinary circulating tumor DNA to predict radiographic progression and response in patients with metastatic lung adenocarcinoma

24. Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers

25. Prognostic value of plasma circulating tumor (ct) DNA KRAS mutations and serum CA19-9 in unresectable pancreatic cancer (PC) patients

26. Monitoring minimal residual disease (MRD) by KRAS mutation burden in urinary or plasma circulating tumor (ct) DNA in colorectal cancer (CRC) patients with resectable liver metastases

27. Non-Invasive Monitoring of Urinary KRAS Circulating Tumor DNA for Treatment Response and Minimal Residual Disease in Patients with Lung Adenocarcinoma

28. Comparative circulating tumor DNA levels for KRAS mutations in patients with nonresectable pancreatic cancer

29. Highly sensitive quantitative detection of circulating tumor DNA in urine and plasma from advanced colorectal cancer patients in aid of early diagnosis of clinically relevant KRAS mutations

30. Abstract LB-170: Droplet digital PCR detection and longitudinal monitoring of BRAF mutations in cell-free urinary DNA of patients with metastatic cancers or Erdheim-Chester disease

31. Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers

32. Detection of BRAF mutations in urine and plasma cell-free DNA: Application to the diagnosis and management of histiocytic disorder patients

33. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders